A proposed staging system for amyotrophic lateral sclerosis

Brain

Volumn 135, Issue 3, 2012, Pages 847-852

  Roche, Jose C ^a,b   Rojas Garcia, Ricardo ^a,c,d   Scott, Kirsten M ^a   Scotton, William ^a   Ellis, Catherine E ^e   Burman, Rachel ^e   Wijesekera, Lokesh ^a   Turner, Martin R ^f   Leigh, P Nigel ^a,g   Shaw, Christopher E ^a   Al Chalabi, Ammar ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

amyotrophic lateral sclerosis; El Escorial criteria; motor neuron disease; natural history; staging

Indexed keywords

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARM; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; DIAPHRAGM; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DYSARTHRIA; DYSPHAGIA; FEMALE; GASTROSTOMY; HUMAN; LEG; MAJOR CLINICAL STUDY; MALE; NONINVASIVE VENTILATION; PRIORITY JOURNAL; PROGNOSIS; SPASTICITY; STAGING SYSTEM; TERTIARY HEALTH CARE; VALIDITY; WASTING SYNDROME; WEAKNESS;

EID: 84857537860     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awr351     Document Type: Article

References (24)

1. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585-91.
2. Boman K, Meurman T. Prognosis of amyotrophic lateral sclerosis. Acta Neurol Scand 1967;43:489-98.
3. Bromberg MB, Brownell AA, Forshew DA, Swenson M. A timeline for predicting durable medical equipment needs and interventions for amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler 2010;11:110-5.
4. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci 1994;124(Suppl.): 96-107.
5. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293-9.
6. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13-21.
7. Chio A, Mora G, Leone M, Mazzini L, Cocito D, Giordana MT, et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 2002;59:99-103.
8. Ganesalingam J, Stahl D, Wijesekera L, Galtrey C, Shaw CE, Leigh PN, et al. Latent cluster analysis of ALS phenotypes identifies prognostically differing groups. PLoS One 2009;4:e7107.
9. Gordon PH, Cheng B, Salachas F, Pradat PF, Bruneteau G, Corcia P, et al. Progression in ALS is not linear but is curvilinear. J Neurol 2010;257:1713-7.
10. Group TAPI-IS. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. Arch Neurol 1996;53:141-7.
11. Henderson R, Diggle P, Dobson A. Joint modelling of longitudinal measurements and event time data. Biostatistics 2000;1:465-80.
12. Huisman MH, de Jong SW, van Doormaal PT, Weinreich SS, Schelhaas HJ, van der Kooi AJ, et al. Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J Neurol Neurosurg Psychiatry 2011;82:1165-70.
13. Ince PG, Lowe J, Shaw PJ. Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. Neuropathol Appl Neurobiol 1998;24:104-17.
14. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet 2011;377:942-55.
15. Mortara P, Chio A, Rosso MG, Leone M, Schiffer D. Motor neuron disease in the province of Turin, Italy, 1966-1980. Survival analysis in an unselected population. J Neurol Sci 1984;66:165-73.
16. Mulder DW, Howard FM Jr. Patient resistance and prognosis in amyotrophic lateral sclerosis. Mayo Clin Proc 1976;51:537-41.
17. Pinto S, Geraldes R, Vaz N, Pinto A, de Carvalho M. Changes of the phrenic nerve motor response in amyotrophic lateral sclerosis: longitudinal study. Clin Neurophysiol 2009;120:2082-5.
18. Radunovic A, Mitsumoto H, Leigh PN. Clinical care of patients with amyotrophic lateral sclerosis. Lancet Neurol 2007;6:913-25.
19. Smith GT. On construct validity: issues of method and measurement. Psychol Assess 2005;17:396-408.
20. Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002;3:15-21.
21. Turner MR, Brockington A, Scaber J, Hollinger H, Marsden R, Shaw PJ, et al. Pattern of spread and prognosis in lower limb-onset ALS. Amyotroph Lateral Scler 2009;11:369-73.
22. Wijesekera LC, Mathers S, Talman P, Galtrey C, Parkinson MH, Ganesalingam J, et al. Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology 2009;72:1087-94.
23. World Federation of Neurology. Research Group on Neuromuscular Diseases Subcommittee on Motor Neuron Disease. Airlie House guidelines. Therapeutic trials in amyotrophic lateral sclerosis. Airlie House "Therapeutic Trials in ALS" Workshop Contributors. J Neurol Sci 1995;129(Suppl.): 1-10.
24. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Lepore V, et al. ALS multidisciplinary clinic and survival. Results from a population-based study in Southern Italy. J Neurol 2007;254:1107-12.